Summary of Significant Accounting Policies (Details 2)	12 Months Ended
	Jun. 30, 2012 USD ($) item	Jun. 30, 2011 USD ($)	Jun. 30, 2010 USD ($)	Jun. 30, 2012 EUR (€)	Jun. 30, 2011 EUR (€)
Inventory
Raw materials	$ 129,000	$ 480,000
Work in process	1,159,000
Total	1,288,000	480,000
Raw materials inventory write-downs	1,300,000	2,000,000
Minimum supply period based on firm, fixed orders and projections from collaborators, used to compute raw materials write downs	12 months
Rolling period of firm, fixed orders for conjugate that the company is required to manufacture	6 months
Rolling period of manufacturing projections for the quantity of conjugate the collaborator expects to need	12 months
Maximum period of firm, fixed orders and/or projections from collaborators considered for capitalizing inventory	12 months
Minimum supply period of raw materials that is not supported by firm, fixed orders and/or projections from collaborators considered to expense inventory	12 months
Charges to research and development expense related to raw material inventory identified as excess	748,000	1,700,000	900,000
Charges to research and development expense to write-down certain raw material inventory to its net realizable value	38,000		28,000
Other Accrued Liabilities
Accrued contract payments	1,773,000	684,000
Accrued clinical trial costs	865,000	1,068,000
Accrued professional services	677,000	652,000
Accrued employee benefits	351,000	277,000
Accrued public reporting charges	208,000	78,000
Other current accrued liabilities	715,000	546,000
Total	4,589,000	3,305,000
Financial Instruments and Concentration of Credit Risk
Number of financial institutions in the U.S. in which cash and cash equivalents are primarily maintained	3
Number of financial institutions in which cash and cash equivalents of the entity are held	2
Net (losses) gains on forward contracts	(173,000)	189,000	(219,000)
Notional amounts of outstanding forward contracts	$ 3,300,000	$ 1,600,000		€ 2,500,000	€ 1,100,000